{
    "clinical_study": {
        "@rank": "43557", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter prospective observational study will evaluate the safety and efficacy of\n      Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic\n      epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be\n      collected from eligible patients until death, withdrawal of consent, loss to follow-up, or\n      study closure."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer, Peritoneal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Prescribed to receive Avastin or already ongoing on treatment with Avastin for\n             advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal\n             cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice\n\n        Exclusion Criteria:\n\n          -  Not eligible for treatment with Avastin according to the local prescribing\n             information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or\n        primary peritoneal cancer initiated on therapy with Avastin"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932125", 
            "org_study_id": "ML28446"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "link": {
            "description": "Clinical Trials Registry - India", 
            "url": "http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5825&EncHid=&userName=Bevacizumab"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560017"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India", 
                        "zip": "600035"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India", 
                        "zip": "600116"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gujarat", 
                        "country": "India", 
                        "zip": "395010"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "zip": "500034"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolkata", 
                        "country": "India", 
                        "zip": "700054"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "zip": "400020"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110060"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110062"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110029"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Indian Multicentric Open Label Prospective Post Marketing Surveillance Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28446 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Indian Health Authority-DCGI (Drug Controller General of India)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 1.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 1.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 1.5 years"
            }, 
            {
                "measure": "Overall response rate (complete response + partial response)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 1.5 years"
            }, 
            {
                "measure": "Clinical benefit rate (complete response + partial response + stable disease)", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 1.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2015", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}